Literature DB >> 19357394

The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes.

James W Vardiman1, Jüergen Thiele, Daniel A Arber, Richard D Brunning, Michael J Borowitz, Anna Porwit, Nancy Lee Harris, Michelle M Le Beau, Eva Hellström-Lindberg, Ayalew Tefferi, Clara D Bloomfield.   

Abstract

Recently the World Health Organization (WHO), in collaboration with the European Association for Haematopathology and the Society for Hematopathology, published a revised and updated edition of the WHO Classification of Tumors of the Hematopoietic and Lymphoid Tissues. The 4th edition of the WHO classification incorporates new information that has emerged from scientific and clinical studies in the interval since the publication of the 3rd edition in 2001, and includes new criteria for the recognition of some previously described neoplasms as well as clarification and refinement of the defining criteria for others. It also adds entities-some defined principally by genetic features-that have only recently been characterized. In this paper, the classification of myeloid neoplasms and acute leukemia is highlighted with the aim of familiarizing hematologists, clinical scientists, and hematopathologists not only with the major changes in the classification but also with the rationale for those changes.

Entities:  

Mesh:

Year:  2009        PMID: 19357394     DOI: 10.1182/blood-2009-03-209262

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  1397 in total

1.  Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial.

Authors:  Jeffrey E Rubnitz; Hiroto Inaba; Gary Dahl; Raul C Ribeiro; W Paul Bowman; Jeffrey Taub; Stanley Pounds; Bassem I Razzouk; Norman J Lacayo; Xueyuan Cao; Soheil Meshinchi; Barbara Degar; Gladstone Airewele; Susana C Raimondi; Mihaela Onciu; Elaine Coustan-Smith; James R Downing; Wing Leung; Ching-Hon Pui; Dario Campana
Journal:  Lancet Oncol       Date:  2010-05-05       Impact factor: 41.316

2.  Cardiac disease in a case of precursor B acute lymphoblastic leukaemia with eosinophilia(ALL/Eo).

Authors:  Mehrnaz Asadi Gharabaghi; Pegah Aghajanzadeh; Ghazal Zahedi; Roghayyeh Borji; Leila Derakhskan; Roya Sattarzadeh; Ramezanali Sharaifian
Journal:  BMJ Case Rep       Date:  2012-01-20

3.  Role of urokinase plasminogen activator receptor (CD87) as a prognostic marker in acute myeloid leukemia.

Authors:  Maha Atfy; Mohamad Eissa; Hossam E Salah; Deena A El Shabrawy
Journal:  Med Oncol       Date:  2011-06-03       Impact factor: 3.064

Review 4.  Practical approach to the patient with hypereosinophilia.

Authors:  Florence Roufosse; Peter F Weller
Journal:  J Allergy Clin Immunol       Date:  2010-06-09       Impact factor: 10.793

5.  Shortcomings in the clinical evaluation of new drugs: acute myeloid leukemia as paradigm.

Authors:  Roland B Walter; Frederick R Appelbaum; Martin S Tallman; Noel S Weiss; Richard A Larson; Elihu H Estey
Journal:  Blood       Date:  2010-06-10       Impact factor: 22.113

Review 6.  Mast cell homeostasis and the JAK-STAT pathway.

Authors:  J K Morales; Y T Falanga; A Depcrynski; J Fernando; J J Ryan
Journal:  Genes Immun       Date:  2010-06-10       Impact factor: 2.676

7.  Prognostication in primary myelofibrosis.

Authors:  Francisco Cervantes; Arturo Pereira
Journal:  Curr Hematol Malig Rep       Date:  2012-03       Impact factor: 3.952

8.  Preclinical and early clinical evaluation of the oral AKT inhibitor, MK-2206, for the treatment of acute myelogenous leukemia.

Authors:  Marina Y Konopleva; Roland B Walter; Stefan H Faderl; Elias J Jabbour; Zhihong Zeng; Gautam Borthakur; Xuelin Huang; Tapan M Kadia; Peter P Ruvolo; Jennie B Feliu; Hongbo Lu; Lakiesha Debose; Jan A Burger; Michael Andreeff; Wenbin Liu; Keith A Baggerly; Steven M Kornblau; L Austin Doyle; Elihu H Estey; Hagop M Kantarjian
Journal:  Clin Cancer Res       Date:  2014-02-28       Impact factor: 12.531

Review 9.  Blinatumomab for the treatment of acute lymphoblastic leukemia.

Authors:  Jason B Kaplan; Marina Grischenko; Francis J Giles
Journal:  Invest New Drugs       Date:  2015-09-17       Impact factor: 3.850

10.  Discrepancy in diagnosis of primary myelofibrosis between referral and tertiary care centers.

Authors:  Cecilia Arana Yi; Ghayathri Jeyakumar; Pedro Medina; Jorge Cortes; Sherry Pierce; Carlos Bueso-Ramos; Hagop Kantarjian; Srdan Verstovsek
Journal:  Leuk Res       Date:  2013-11-13       Impact factor: 3.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.